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Mutations in the LRRK2 gene are the most common cause of genetic Parkinson’s disease. Although the mechanisms
behind the pathogenic effects of LRRK2 mutations are still not clear, data emerging from in vitro and in vivo models
suggests roles in regulating neuronal polarity, neurotransmission, membrane and cytoskeletal dynamics and protein
degradation.
We created mice lacking exon 41 that encodes the activation hinge of the kinase domain of LRRK2. We have
performed a comprehensive analysis of these mice up to 20 months of age, including evaluation of dopamine
storage, release, uptake and synthesis, behavioral testing, dendritic spine and proliferation/neurogenesis analysis.
Our results show that the dopaminergic system was not functionally comprised in LRRK2 knockout mice. However,
LRRK2 knockout mice displayed abnormal exploratory activity in the open-field test. Moreover, LRRK2 knockout mice
stayed longer than their wild type littermates on the accelerated rod during rotarod testing. Finally, we confirm that
loss of LRRK2 caused degeneration in the kidney, accompanied by a progressive enhancement of autophagic
activity and accumulation of autofluorescent material, but without evidence of biphasic changes.
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Mutations in the LRRK2 gene, originally described in 2004,
have now emerged as the most important genetic finding in
Parkinson’s disease (PD) [1,2]. Incredibly, the most com-
mon mutation LRRK2 G2019S accounts for up to 40 % of
Parkinsonism in populations of certain ethnic descent [3-5].
LRRK2 mutations also account for around 2% of sporadic
Parkinsonism and two risk factors have been identified in
Asian populations [6-9]. LRRK2-associated PD is a late
onset disease and in general the disease resembles idio-
pathic PD both clinically and pathologically.
LRRK2 has been linked to neurite outgrowth, vesicular
trafficking, protein translation and autophagy [10]. Ana-
lysis of mutant transgenic and knock-in models* Correspondence: Melrose.heather@mayo.edu
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reproduction in any medium, provided the orexpressing physiological levels of LRRK2 has led to an
emerging theme that aberrant LRRK2 leads to subtle
alterations in dopamine neurotransmission, albeit in the
absence of dopaminergic neuronal loss [11]. Imaging
studies in asymptomatic PD patients show the earliest
detectable changes occur in the dopamine transporter
and the same holds true for asymptomatic LRRK2
[12,13] and SNCA (alpha-synuclein) patients [14-16].
Neurotransmission alterations in mutant LRRK2 models
may be similar to early preclinical events, suggesting an
early involvement in dopamine dysfunction.
The expression profile of LRRK2 mRNA suggests that
LRRK2 is unlikely to be an essential developmental pro-
tein [17]. In adult rodent brain, LRRK2 mRNA is found
at highest levels in dopamine receptive areas particularly
the striatum [18-22]. However, protein expression of
LRRK2 is abundant throughout the brain including the
substantia nigra, striatum, hippocampus, thalamus,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in multiple brain functions (i.e. memory, sensory, emo-
tion) and not just those involved in motor control.
To further study the role of LRRK2 in the brain, we have
developed LRRK2 knockout mice by ablating exon 41 in
the kinase domain of LRRK2. We have performed a com-
prehensive analysis to study the effect of loss of LRRK2;
this includes a thorough investigation of the dopaminergic
system, extensive behavioral tests to examine motor, co-
ordination and emotional behavior, as well as neuropatho-
logical analyses. We find little evidence that loss of LRRK2
impacts dopaminergic neurotransmission or striatal beha-
viors, however we present data showing changes in the ex-
ploratory and motor co-ordination behaviors in these
mice. These findings may be an important consideration
for future anti-LRRK2 therapies.
Results
Generation of murine LRRK2 knockout mice
The targeting strategy for generation of LRRK2 knockout
(KO) mice is shown in Figure 1A. Homozygous mice
received from Ozgene PLC were bred to Jackson C57BL6/
J mice and subsequent heterozygous offspring were bred
together to obtain wild type (WT), heterozygous (HET)
and KO animals. Northern blotting analysis with a probe
designed to LRRK2 exon 24–27 confirmed the absence of
the ~9 kb LRRK2 mRNA transcript in KO mice and a
reduced transcript signal in the HET mice (Figure 1B).
Similarly, immunoblotting confirmed absence of LRRK2
protein band in the KO mice and a diminished signal in
HET mice (Figure 1C). Immunohistochemistry also
revealed specific signal in the WT compared to KO
(Figure 1D).
To determine if any compensatory mRNA changes oc-
curred in the paralog LRRK1, we used quantitative Taqman
assay with a probe to murine LRRK1 to compare WT, HET
and KO mice. No significant alterations in LRRK1 mRNA
levels were observed in any of the brain regions tested. We
also checked mRNA levels of SNCA, MAPT or PARKIN
and found no differences (Additional file 1: Figure S1).
LRRK2 KO mice were fertile and appeared to be healthy
from birth, with body weights comparable to WT litter-
mates within the study period. HET x HET breedings
yielded Mendelian ratios in line with expected inheritance
(from over 70 litters 24.4 % WT, 51.6 % HET, 24 % KO).
Subsequent characterization experiments were performed
to compare KO and WT mice at different aging time
points. Due to animal costs and space restraints, we
included a HET group in some, but not all, of these
analyses.
Dopaminergic system characterization
LRRK2 expression is normally found in high levels in the
striatum so we reasoned that loss of LRRK2 may impactthe functional integrity of the nigro-striatal dopa-
minergic pathway. To determine if dopamine neurons or
their processes were altered in the substantia nigra, we
performed stereological counts of tyrosine hydroxylase
(TH) positive neurons and dendrites in KO and WT
mice aged 18–20 months. No differences in neuronal esti-
mates were observed between KO mice (mean estimate ±
SEM; 13,766 ± 471) compared to their WT littermates
(12,267 ± 481) (Figure 2A). Similarly, there were no differ-
ences between dendritic estimates for WT (149,763 ±
6213) and KO (153,873 ± 4351) (Figure 2B). Next, we
examined dopamine axonal neurochemistry by analyzing
total dopamine content in striatal lysates by HPLC from
10 month and 18 month KO mice and WT littermates
(Figure 2C-G, data shown only for 18 months) and found
dopamine and its metabolite 3,4-dihydroxyphenylacetic
acid (DOPAC), and homovanillic acid (HVA) levels were
equivalent in KO and WTanimals at both time points.
Since total striatal dopamine includes dopamine that is
stored, synthesized, released and taken up, we hypothe-
sized that we may observe differences in KO mice by
investigating these mechanisms independently. First, we
performed microdialysis to measure extracellular release
of dopamine in vivo. Extracellular dopamine levels were
measured before and after KCl-evoked dopamine response
in WT, HET and KO mice aged 3–4 months of age
(Figure 2H). Baseline levels of dopamine were not found
to differ between WT (0.13 ± 0.06 pg/μl), HET (0.15 ±
0.06 pg/μl) or KO mice (0.16 ± 0.07 pg/μl). When post-
KCl dopamine levels were normalized to the average of
their individual basal dopamine levels (i.e. % response) no
significant differences were observed (Figure 2I). Next, we
examined dopamine uptake in the WT, HET and KO mice
using a radioactive uptake assay with [3H] dopamine. Up-
take was comparable across the three groups suggesting a
functionally intact dopamine transporter (Additional file
2: Figure S2A). Concluding that release, storage and up-
take of dopamine appear to be normal, we then examined
D2-autoreceptor mediated synthesis and release, which is
one of the feedback mechanisms in the striatum. It is well
known that antagonizing pre-synaptic D2 autoreceptors
can remove this feedback inhibition and cause increased
synthesis as well as release of dopamine [24]. WT, HET
and KO mice were treated with the D2 receptor antagon-
ist raclopride, sacrificed 30 min later and HPLC analysis
performed to quantify dopamine and metabolites. As
expected, dopamine turnover, as measured by the ratio of
dopamine metabolites to stores of dopamine increased
dramatically [One way ANOVA ps< 0.0001 for DOPAC/
dopamine and HVA/dopamine] following treatment with
raclopride (Additional file 2: Figure S2B, C). However,
Tukey’s post hoc comparisons did not reveal differences in
this response between WT, HET or KO mice, suggesting
that autoreceptor-mediated feedback is normal in the
Figure 1 Generation and expression characterization of LRRK2 KO mice. (a) Schematic diagram (courtesy of Ozgene PLC) showing targeted
locus. Exon 41 was flanked with LoxP sites to allow deletion with Cre recombinase. PKG-Neo-pA-SD-IS is Ozgene’s standard selection cassette and
was inserted downstream of exon 41. The PKG-neo cassette was also flanked by FRT sites to allow FLPe recombinase deletion. The targeting
vector was constructed from three fragments, the 5’homology arm, the 3’ homology arm and the lox P arm, which were generated by PCR.
Splicing of exon 40 to 42 causes a frame shift mutation, with the introduction of an early stop codon (TGA). (b) Northern blot hybridized with a
probe to LRRK2 exon 24–27 showing absence of transcript in KO and diminished transcript in HET. A histone probe was used as loading control.
(c) Immunoblot with LRRK2 antibody 1182E, raised to amino acids 841–960 showing the absence of LRRK2 protein in KO and diminished signal
in HET. GAPDH was used as a loading control. (d) Immunohistochemistry with MJFF2 c41-2 antibody showing WT and KO brain sections at the
level of the striatum. Specific signal is seen in the WT compared to KO. Rabbit IgG was used as an isotype control. Boxes depict enlarged images
to the right. Scale bar 50 microns.
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40 phosphorylated TH after raclopride treatment was also
observed (indicating increased synthesis), but this response
was not different between WT, HET or KO mice (data not
shown). Finally, we examined striatal receptor density for
both dopamine D1 and D2 receptors by autoradiography in
10 and 18 month old WT and KO mice and no differences
were observed (Additional file 3: Figure S3A-D).
Analysis of striatal dendritic spines
We have previously shown that LRRK2 G2019S trans-
genic mice have impaired neurite outgrowth in vitro [25]
and in vivo [26] as well as a reduced number of mature
spines in the hippocampus [26]. We have also reported
that neurite outgrowth was increased in both midbrain
and hippocampal cultures derived from LRRK2 KO mice
[25]. As LRRK2 has previously been linked to ERM pro-
teins and the actin cytoskeleton [27-31] we hypothesized
that the loss of LRRK2 in the striatum in KO mice, anarea where it is normally highly expressed, may impact
on striatal dendritic spines. We counted spine number
in Golgi-Cox labeled medium spiny neurons (MSN) of
brains from aged (18+ months) KO and WT mice.
Spines were classified into different morphological types
[32]. No differences were found in spine numbers
between in KO and WT mice suggesting that lack of
LRRK2 has no effect on MSN spine dynamics in vivo
(Additional file 4: Figure S4).
Proliferation / Neurogenesis studies
As LRRK2 is normally expressed in the hippocampal den-
tate gyrus and proliferation, neurogenesis and migration
are impaired in G2019S BAC mice [26], we sought to as-
certain whether loss of expression has an impact on cell
proliferation. We analyzed the effect of loss of LRRK2 on
newly generated cells in the hippocampal dentate gyrus
after a single injection of BrdU. Unbiased stereological
counting methods were applied to estimate the number of
Figure 2 Dopaminergic characterization in LRRK2 KO mice. (a,b) Unbiased sterological estimates for TH-positive (a) neurons and (b)
dendrites in the substantia nigra reveal no difference between WT and LRRK2 KO mice. Counting was performed using optical fractionator probes
in TH stained sections from 18 month old WT and KO mice. (c-e) Dopamine axon terminal neurochemistry is normal in LRRK2 KO mice. HPLC
analysis of total striatal content of dopamine (da) and its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). (f-g)
Mean of individual animal turnover ratios of DA to metabolites DOPAC and HVA. (h-i) In vivo microdialysis reveals similar baseline and KCl-evoked
levels of extracellular DA in WT, HET and KO mice (i). DA levels were plotted as a percentage of each individual animal’s mean baseline levels to
compare response over time (h) % Response did not differ between WT, HET and KO mice. Dopamine levels were measured by HPLC from
dialysates collected from the striatum. All data are presented as mean ± SEM.
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proliferation between KO and WT mice (Additional file 5:
Figure S5A). Since doublecortin (DCX) expression levels
in adult brain reflect neurogenesis [33], we also performed
counts on DCX labeled neurons in the hippocampus and
these were also found to be comparable in KO and WT
mice (Additional file 5: Figure S5B) suggesting normal
neurogenesis occurs in KO mice.
Neuropathology
Hameotoxylin and eosin revealed morphology of KO
mouse brains to be normal up to 20 months of age. To
assess mice for neuropathological alterations we examined
young (3–6 months), middle aged (10–13 months) and
aged (18+ months) WT, HET and KO mice for a variety of
markers associated with Parkinson’s disease pathology in-
cluding alpha-synuclein, tau and Iba-1. In agreement with a
previous report [34], no overt differences were observedwith any of these markers between WT, HET and KO mice.
As we have previously shown alterations in tau regulation
in our BAC mutant LRRK2 G2019S model, we performed
quantitative immunoblotting with tau antibodies (tau-5,
CP-13 and tau-1) in lysates from aged WT and KO mice.
Our results indicate that tau regulation is normal in KO
mice (Additional file 6: Figure S6).
Behavioral Analysis
Open-field Test
In the initial characterization, we focused on the analysis of
spontaneous exploratory locomotor behavior evaluated in
the open-field test. The open-field test assesses spontaneous
exploration of mice as well as their emotional response
after being exposed to much larger than a home cage and
brightly illuminated unfamiliar environment [35-37]. The
rationale behind this approach was based on evidence that
anxiety disorders, which affect about 40 % of PD patients
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onset of motor symptoms, such as bradykinesia, rigidity,
resting tremor and postural instability in PD by decades
[39]. The open-field test, which combines the evaluation of
anxiety as well as spontaneous locomotor activity, therefore
presents an appropriate paradigm for the phenotyping
characterization of the KO mice. The test has been success-
fully used with other familial Parkinson disease mouse
models, for example mice deficient in parkin gene [40].
We characterized the behavior of KO and WT mice in
the open-field test, adopting longitudinal experimental de-
sign, at a young (7 months) and older (16 months) time
point. The evaluation was done in one 5-min session at
each age in order to minimize the saving effect and habitu-
ation to the test due to repeated testing. Data was analyzed
by repeated measures ANOVA followed by Student’s t-tests
for independent samples (to assess the genotype effect at
each testing age) and matched-pairs samples (to assess the
age effect within each genotype).
Overall analysis of the exploration of the open-field arena
by KO and WT mice revealed no differences in the length
of walking distance, walking speed or onset of exploration
between the genotypes. The KO mice tended to spend
more time on longer (> 5 s) rests than WT mice during
their exploration (p< 0.05, ANOVA, genotype effect), how-
ever, high variability of this behavior did not yield signifi-
cant differences at α = 0.05 at each age of testing
(Figure 3A). The number of rests and shorter (< 5 s) stops
did not differ between the genotypes.
Mice of both genotypes explored the center of the arena
less at 16 months than at 7 months test (15.9 s ± 1.6 for 16-
month and 25.0 s ± 3.5 for 7-month mice respectively, p<
0.001, ANOVA, age effect). However, KO mice explored
the center of the open-field arena significantly less than the
WT mice (15.0 % ± 2.4 and 25.9 % ± 2.8 of time averaged
across age for KO and WT mice respectively, p< 0.01,
ANOVA, genotype effect). The difference was significant at
both at 7 (p< 0.05, t-test) and 16 (p< 0.01, t-test) months
of age (Figure 3B).
This shorter time of exploration of the inner area
of the field by the KO mice was likely due to their
increased thigmotaxic (wall hugging) behavior (p<
0.001, ANOVA, genotype effect). The KO mice spent
between 18 % to 87 % and 53 % to 91 % of their ex-
ploratory activity moving within close proximity of
the wall during 7- and 16-month tests respectively. In
contrast, the WT controls showed thigmotaxic behav-
ior within a range of 9 % to 48 % and 36 % to 66 %
during respective tests. Representative examples of
the exploratory paths, reflecting the differences in the
thigmotaxic behavior, are presented in Figure 4. Over-
all, the thigmotaxic behavior increased with age (p< 0.001,
ANOVA age effect), with no significant interaction between
the genotype and age factors. The differences inthigmotaxic behavior between the genotypes were signifi-
cant at both 7 (p< 0.01, t-test) and at 16 (p< 0.001, t-test)
months of age (Figure 3C).
Our analysis also revealed that overall, the exploratory
paths of KO mice were less curvy and tortuous as com-
pared to the paths of the WT counterparts (p< 0.001,
ANOVA, genotype effect) and path tortousity was lower
in mice of both genotypes during tests at 16 months
(p< 0.001, ANOVA, age effect). The specific compari-
sons revealed a significant genotype effect on path
tortuosity only at 16 months (p< 0.001, t-test,
Figure 3D).
Lastly, the KO mice approached an object placed in the
center of the arena with longer latencies than WT mice (p
< 0.05, ANOVA, genotype effect). In general, KO mice
tended to spend less time exploring the object than WT
mice (averaged across age 4.96 ± 0.09 and 9.45 ± 0.15 sec-
onds respectively, p = 0.06, ANOVA, genotype effect). The
borderline significance of the genotype effect was due to
high variability in this behavior at 7-months (Figure 3E). At
16 months, however, the KO mice explored the object sig-
nificantly less (p <0.05, t-test, Figure 3E). The KO mice also
approached the object less frequently (p< 0.05, ANOVA,
genotype effect), with significant differences at each age of
testing (ps< 0.05, t-test for 7 and 16 months, Figure 3F).
All mice approached the object less frequently when tested
at the older age (p< 0.05, ANOVA, age effect).
In summary, our results indicate that the KO mice
showed abnormal spontaneous exploratory behavior in
the open-field test, which was characterized by signifi-
cantly higher thigmotaxic exploration of the arena. This
result might be indicative of increased anxiety in the KO
mice. Thigmotaxic behavior has been previously
reported as a reliable measure of anxiety in the pre-clin-
ical studies testing anxiolytic drugs [41]. In spite of the
observed differences, we interpret these results cau-
tiously, since most of the open-field test measures are
interdependent [37]. We focused our emphasis on thig-
motaxic behavior since it is likely that the initial preva-
lent engagement in this behavior affects other measures,
like the exploration of inner area (r2 = 0.49, and r2 = 0.72
for 7 and 16 months respectively, ps = 0.001), and path
tortuosity (r2 = 0.38 – 7 months, and r2 = 0.45 –
16 months, ps< 0.001).
Motor tests
Next, in a separate 7 month old cohort, we examined
motor behavior in KO mice and compared this to both
WT and HET littermates. Motor co-ordination/balance
was examined by rotarod performance and gait was
examined by digigait footprint analysis. Since the
weights of the mice in each genotype did not differ sig-
nificantly (p> 0.2, ANOVA), body weight was not used
as a covariate in the analysis [42]. Analysis of
Figure 3 Open-field test reveals abnormal exploratory behavior in LRRK2 KO mice at both 7 and 16 months of age. (a) KO mice tended
to spend longer time on rest stops longer than 5 seconds. (b) KO mice spent significantly less time exploring the inner area of the open-field at
both testing ages. (c) KO mice displayed significantly greater thigmotaxic (wall hugging) behavior at both testing ages. (d) KO mice take less
turns and their travel path is less curvy than WT mice, this was significant at 16 months. (e) Aged KO mice spend less time exploring the object
than their WT counterparts. (f) KO mice of both age time points approach the object less frequently. Data presented as mean ± SEM. Data was
analyzed by repeated measures ANOVA (see results section for full details) followed by Student’s t-tests for independent samples (to assess the
genotype effect at each testing age) and matched-pairs samples (to assess the age effect within each genotype). The p-values on the graphs
reflect the independent sample t-test results. ** p <0.01, ***p <0.001.
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differences between the groups (p< 0.02, ANOVA). Sub-
sequent, post-hoc analysis revealed that KO mice per-
formed significantly better than their WT littermates,
spending ~20 % (p< 0.01, Tukey’s test) longer on the rod
(Figure 5).
The gait analysis was performed at three different
speeds (14, 18 and 24 cm/sec) and compared a num-
ber of spatial and temporal indices between WT, HET
and KO mice. Overall, there were no significant dif-
ferences between the genotypes for stride lengths or
any other of the recorded indices (Table 1) suggesting
gait and thus striatal function remains intact.Inflammatory and degenerative alterations in kidney of
LRRK2 KO mice
Two groups have previously identified abnormalities in the
kidneys of LRRK2 KO mice including morphological
changes, lysosomal and autophagic alterations, vacuoliza-
tion and accumulation of pigment [34,43]. We examined
kidneys from mice aged 3 to 20 months and also observed
coloration (darkening) changes beginning as early as
3 months (Figure 6A). Significant enlargement was
observed in the kidneys from the oldest mice (mean ±
SEM; for KO female 0.23 ± 0.01 g and female WT 0.19 ±
0.01 g, p< 0.05 t-test; male KO 0.35 ± 0.02 g and male WT
0.22 ± 0.01 g, p< 0.001 t-test). At the gross level, kidneys
Figure 5 Alterations in motor co-ordination behavior in LRRK2
KO mice. Motor co-ordination and balance was tested by
accelerating rotarod analysis in a 7-month cohort of WT, HET and KO
mice. The speed of the rod was set to 4-40 rpm acceleration,
increasing 1 rpm every 5 seconds. KO mice significantly
outperformed their WT littermates. Data are plotted as mean ± SEM
and were analyzed by ANOVA with Tukey’s post-hoc comparisons. **
p <0.01.
Figure 4 LRRK2 KO mice exhibit thigmotaxic behavior in the
open-field test. Examples of movement traces from open-field trials
show the range of thigmotaxic behavior from (a) 7 months and (b)
16 months old WT and KO mice. This thigmotaxic behavior was
typical of LRRK2 KO mice, although a few displayed normal
exploration patterns.
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(Figure 6A) therefore we limited subsequent analysis to KO
and WT. Hematoxylin and eosin staining revealed inflam-
matory abnormalities, vacuolization and pigmentation in
KO kidneys as young as 3 months, which was progressive
with age (Figure 6B). We performed histological staining
for a number of different markers including p62 (anubiquitin-binding protein involved in cell signaling, oxida-
tive stress and autophagy, found to be upregulated in many
neurodegenerative diseases), Periodic acid-Schiff (PAS) stain
for glycoproteins, iron (Gomori's Prussian blue) and mel-
anin (Fontana-Masson) staining for pigment and immuno-
histochemistry for PD related proteins alpha-synuclein and
ubiquitin. The KO kidney pigment was negative for iron
and melanin. PAS staining revealed abnormal granular
staining reminiscent of lipofuscin in the proximal tubules of
KO mice as young as 3 months of age, progressing at
12 months and becoming severe by 18 months (data not
shown). These granular inclusions were also auto-
fluorescent, the intensity increasing with age (Figure 6B).
Increased p62 immunostaining in the same cells in KO
mice was observed as early as 3 months of age, although
quantitative differences were not detectable by immunoblot
at this age (Figure 7). The intensity of p62 immunostaining-
progressed with age, and by 12 months quantitative differ-
ences were evident. By 18 months the KO mice had on
average a 15-fold increase (p< 0.01, t-test) in immunoblot
relative band density compared to WT controls (Figure 7).
We were unable to corroborate the previous reports of
increases in alpha-synuclein or ubiquitin [34,44] in
KO mice neither by immunohistochemistry nor by
immunoblotting.
To further examine the granular pathology at the ultra-
structural level, we performed electron microscopy in
kidneys from 18 months old KO and WT mice (Figure 6C).
Tubular epithelial cells in the renal cortex of KO kidney
were found to contain degenerating debris and accumula-
tion of pigment resembling lipofuscin, both absent from
Table 1 Normal gait in LRRK2 KO mice. Mouse gait dynamics were obtained using a motorized treadmill by ventral
plane videography and analyzed with DigiGait® software
Average gait dynamics in WT, HET & KO mice
treading at a speed of 24cm/sec
Parameter WT (n=9) HET (n=8) KO (n=8) p
Stride length (cm) 6.42 ± 0.57 6.38 ± 0.71 6.09 ± 0.50 ns
Stride frequency (steps/sec) 3.84 ± 0.37 3.88 ± 0.46 4.06 ± 0.32 ns
Stride duration (sec) 0.267 ± 0.023 0.265 ± 0.029 0.254 ± 0.020 ns
% Stance duration 58.5% ± 3.3% 59.5% ± 5.5% 59.1% ± 4.4% ns
% Swing duration 41.5% ± 6.2% 40.5% ± 6.0% 41% ± 3.9% ns
Step angle (deg) 61.1 ± 9.6 64.3 ± 6.5 59.1 ± 6.8 ns
Fore paw angle (deg) 9.63 ± 1.68 11.76 ± 5.04 12.51 ± 4.13 ns
Hind paw angle (deg) 18.97 ± 3.13 20.08 ± 1.81 18.43 ± 2.42 ns
Total steps (No./paw) 17 ± 5 18 ± 4 18 ± 4 ns
Hind limb shared stance (sec) 0.047 ± 0.026 0.050 ± 0.018 0.036 ± 0.013 ns
Values are means ± StdDev and were analyzed by one-way ANOVA;
ns = p>0.05.
Gate indices were not different between WT, HET and KO mice. Data are plotted as mean ± SD and were analyzed by ANOVA.
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mal tubular epithelial cells were still present and no evi-
dence of abnormal mitochondria was found. Following on
from conflicting reports of impaired/biphasic or no change
autophagy in LRRK2 KO mice [34,43,44] we performed im-
munoblotting with LC-3 antibody in kidney lysates from
mice aged 3, 12 and 18 months old. No significant differ-
ences were seen at the 3 and 12 month time-point. How-
ever in KO mice aged 18 months we observed a significant
2.8 fold increase in intensity of the LC-3 II band (p< 0.05,
t-test) indicating an increase, rather than the previously
reported decrease.
Discussion
In this report we present dopaminergic, behavioral and
pathogenic characterization of mice lacking LRRK2 to
20 months of age. Our most significant findings are
observed at the behavioral level, which reveal normal
motor gait but altered open field and motor co-ordin-
ation behavior in LRRK2 KO mice. In the open-field test
KO mice displayed an increased thigmotaxic behavior,
walking along the wall of the apparatus, which resulted
in reduced path tortuousity. This phenotyping profile
was characteristic both at 7 and 16 month of age, with
no indication of progressing deterioration in this pheno-
type. It has been reported that the measures obtained in
the open-field test are variable and labile [45], which
could account for the lack of significant interactions be-
tween age and genotype in our study. Increased thigmo-
taxic behavior is often attributed to an increase in
anxiety during the exploration of new environment
[35,41] or lack of flexibility in changing ongoing behav-
ior [46]. Follow up studies to examine progression of
these behaviors in KO mice will require larger cohortsizes and will focus on complementary to the open-field
tests evaluating anxiety in mice, including rescue with
anxiolytic agents. Interestingly, we have previously
reported very similar open field behaviors in our mutant
G2019S BAC mice [47] which formulates the idea this
phenotype could be a loss of function behavior. While
current thinking favors a gain of function role for aber-
rant LRRK2, the phenotype reported in LRRK2 KO kid-
neys [34,43] has somewhat challenged this, leading to
speculation of cell-specific LRRK2 roles.
Surprisingly, our study revealed that LRRK2 KO mice
stayed persistently longer on the rotating rod, despite no
obvious differences in their gait characteristics. Coinciden-
tally, the Michael J Fox foundation recently posted online
data detailing phenotypic testing of their LRRK2 KO
model being characterized at Wil Research and this data
showed a trend for enhanced rotarod performance in
4 month old KO mice compared with WT controls http://
www.pdonlineresearch.org/sites/default/files/MJFF%
20Animal%20Models%20Data%20-%20Oct%2031.pdf).
The rotarod test is known to be sensitive to cerebellar
function and deficits in cerebellar purkinje neurons gener-
ally result in a reduced rotarod performance. In the litera-
ture there are only a few reports of genetic mouse models
exhibiting enhanced rotarod performance compared with
their wild type/ non-transgenic littermates. Examples in-
clude a mouse model for Down’s syndrome (Ts65DN)
[48], heregulin (a ligand for tyrosine receptor kinase) mu-
tant mice [49], an epilepsy model deficient in a repair pro-
tein L-isoaspartate (d-aspartate)-O-methyltransferase
(Pcmt1−/−) [50] and Huntington triplet deletion mice
Hdh (ΔQ/ΔQ) mice [51]. Both the Ts65DN and heregulin
model had known cerebellar morphological changes
[48,49]. Morphological and pathological analysis of the
Figure 6 LRRK2 KO mice develop degeneration in the kidney from an early age. (a) Comparison of perfused kidneys extracted from WT,
HET and KO mice at 3, 6, 12 and 20 months of age. Coloration changes were observed as early as 3 months in KO mice. HET kidneys were not
affected. (b) Histopathology of kidney reveals morphological changes. H&E at 3 months shows pigmentation in proximal tubule (arrow). H&E at
18 months shows extensive vacuolization (white arrow) and pigmentation (arrowhead). Positive p62 staining can be seen at 3 months in KO and
is extensive by 18 months. Pigmentation in tubules, most likely to be lipofuscin, is autofluorescent in rhodamine channel at both 3 and
18 months in KO. Scale bar is 50 microns. (c) Electron microscopy in KO kidney reveals degenerative changes at the ultrastructural level in renal
cortex tubular epithelial cells from 18 month old KO mouse. (i) Normal epithelial cell in WT mouse. (N) nucleus. (ii) Degenerating debris (d) in
tubular epithelial cell in KO. (iii) Higher power image from KO showing normal mitochondria (M), lipid (Lp) probably lipofuscin and degenerative
structure, probably lysosomal-containing lipid. (iv) Higher power image from KO of degenerative structure showing extensive debris.
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veal any obvious structural differences, however given the
high expression of LRRK2 in the cerebellum, further stud-
ies examining cerebellar neurochemistry/function may be
warranted. In the heregulin mutant and Pcmt1−/− models,
enhanced rod performance was also accompanied by
hyperactivity [49,50] which we did not observe. However,
like our LRRK2 KO mice, the Pcmt1−/− mice also dis-
played significant thigmotaxic behaviors in addition toenhanced rotarod phenotype. Our rotarod result together
with the results obtained in the open-field test might indi-
cate inability of termination of ongoing behavior, which
resulted in higher ceiling performance of KO mice in the
rotarod test.
It is also important to note that aside from the cere-
bellum, enhanced rod performance could also be attrib-
uted to central (i.e. heart) and/or peripheral effects (i.e.
muscle). Since LRRK2 is expressed in both heart and
Figure 7 Quantitative differences in p62 levels and LC3-II/LC3-I ratio in aged LRRK2 KO mice. (a) Representative LC3 and p62 immunoblots
of insoluble fraction kidney lysates from 3-, 12- and 20-month old WT and KO mice. Visibly more p62 is seen in both 12- and 20-month old mice. LC3-II
levels are also visibly increased in 20-month old KO mice. (b) Graphical presentation of densitometric quantification of immunoblots from N= 5-7 animals
for each group. Alzheimer (AD) brain lysate was used as a control. LC3 data are expressed as a ratio of LC3-II/LC3-I. The ratio of LC3-II/LC3-I was significantly
increased by 20 months, indicating an increase in autophagy. p62 data was expressed as % intensity, normalized to the lowest densitometric band on
each blot. A significant increase was observed in KO mice at 12 and 20 months. Data are presented as mean ± SEM and were analyzed by either
Student’s t-test or Mann Whitney non-parametric comparisons. ** p <0.01, ***p <0.001.
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of heart and muscle may also be revealing.
LRRK2 KO mice have normal lifespans and do not
have any compensatory changes in LRRK1 or other PD
related mRNAs. In agreement with previous reports, and
consistent with the lack of striatal-related motor pheno-
types, we did not observe any changes in total striatal
dopamine levels nor did we observe nigral neuronal loss.
Given that several mutant LRRK2 models have normaltotal dopamine levels, but still exhibit subtle defects in
extracellular release, we extended on the studies of
others [34,43] and performed in vivo microdialysis in
LRRK2 KO, HET and WT mice. Endogenous extracellu-
lar levels of dopamine were found to be normal in KO
and HET mice compared with WT, as were post-KCl
stimulation levels. Taken together, our data suggest that
the dopamine system is functionally intact in LRRK2 KO
mice. Future studies to examine extracellular release of
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serotonin in the hippocampus/amygdala may be more
informative given the abnormal behaviors in the open-
field.
Curiously, unlike the G2019S BAC mice, LRRK2 KO
mice do not appear to have any defect in neurogenesis,
since proliferating cells and DCX counts were similar to
WT mice. Dentate gyrus neurogenesis is thought to be
involved in regulation of emotion [52,53] and we previ-
ously theorized that the impaired neurogenesis and anx-
iety phenotype may be linked in G2019S mice [26].
However, in this instance the unaltered neurogenesis in
LRRK2 KO mice rules out this idea.
Neuropathological analysis of brains from LRRK2 KO
mice does not reveal any PD-related pathology or striatal
dendritic spine alterations and tau regulation also
appears to be normal in KO mice. In agreement with
others [34,43] we do observe a marked kidney pheno-
type, which in our mice is characterized by discoloration,
enlargement, inflammatory and degenerative changes.
The phenotype occurs in LRRK2 KO (but not HET)
from both genders and some features are observed as
early as 3–4 months including discoloration, inflamma-
tion, increased p62 immunopositive cells and pigmenta-
tion. What is curious is that we observe the opposing
effect on autophagy reported by Tong el al, in that we
see elevated, rather than a decreased levels of LC3 II, in-
dicating increased autophagy in the oldest (18–
20 months) mice, and no indication of a biphasic re-
sponse. Herzig et al recently reported that they saw no
changes in LC3-II in their KO line [43], however the
data presented suggests they only examined mice up to
14 months of age for this marker and we only saw quan-
tifiable differences at the 18 month time point. Our data
points toward a compensatory attempt to counteract the
degeneration and pigment accumulation. Although one
would expect all LRRK2 knockout models to exhibit
similar phenotypes, it is possible that subtle differences
in strain background, targeting and breeding strategies
may alter phenotypic progression, and perhaps if we
were able to age our mice long enough, we may well ob-
serve a decrease in autophagy and alpha-synuclein accu-
mulation in the kidney as the degenerative phenotype
progresses.
Conclusions
In summary, we report mice lacking LRRK2 via targeted
removal of the kinase domain have a normal dopamin-
ergic system and do not develop any pathological fea-
tures of PD. Our detailed behavioral analysis has
revealed open-field phenotypes in KO mice, warranting
further study into the role of LRRK2 and limbic system
behaviors/neurochemistry. Loss of LRRK2 has a positive
impact on rotarod performance, implying possibleinvolvement in cerebellar function and sensory proces-
sing, although the mechanisms are unclear at this time.
Finally, we confirm the impact of loss of LRRK2 on the
kidney, which reiterates the important consideration of




All animal procedures were approved by the Mayo
Clinic Institutional Animal Care and Use Committee
and were in accordance with the National Institute of
Health Guide for the Care and Use of Laboratory Ani-
mals (NIH Publications No. 80–23) revised 1996.
Generation of targeted LRRK2 knockout mice
LRRK2 knockout (KO) mice, generated at Ozgene PLC
(Australia) were created utilizing a construct designed to
ablate LRRK2 exon 41. Regions of 5’ homology (4 kb)
and 3’ homology (4.7 kb) were used to drive the homolo-
gous recombination event by standard gene targeting
techniques in C57BL/6 Bruce4 embryonic stem (ES)
cells [54]. Following electroporation of the targeting
construct, cells were selected for neomycin (Neo) resist-
ance. Targeted ES cells were confirmed by Southern
blotting and PCR. Euploid, targeted ES cells were then
microinjected into Balb/cJ blastocysts and reimplanted
into pseudopregnant dams. Resultant chimeras were
bred to C57BL/6 J breeders to establish transmission.
Black (i.e. those with the ES cell germline) progeny that
were heterozygous for the gene-targeted allele were then
bred to Cre recombinase “deleter” mice on C57BL/6 J
background (Ozgene) to allow excision of the exon 41
and Neo selection cassette, which were flanked by lox P
sites. Cre was then removed by breeding to C57BL/6 J
wild type mice. Resultant mice were then transferred to
our colony and bred to homozygosity, maintained on the
C57BL/6 J background. Single nucleotide polymorphism
analysis with 124 evenly spaced markers covering the
mouse genome indicated that the strain was congenic
on C57BL/6 with no evidence of any contaminating in-
bred strain.
Routine genotyping was performed by a PCR-based
strategy utilizing intronic primers that span exon 41
(forward 5’CTACCAGGCTTGATGCTTTA’3, reverse
5’TCTGTGACAGGCTATATCTC’3) that yielded a
471 bp band in wild type (WT), ~220 bp band in KO
and both bands in heterozygotes (HETS).
Northern Blotting
Total RNA was extracted using Trizol® reagent (Invitro-
gen) according to manufacturer’s instructions. Two mice
from each genotype (WT, KO, HET) were used for ana-
lysis. Total RNA (12 μg) was prepared in 1X MOPS,
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mamide, denatured at 65°C. Samples were electrophor-
esed on a denaturing gel (1 % (w/v) agarose 0.7 %, (v/v)
formaldehyde, 1X MOPS, 0.005 % (v/v) ethidium brom-
ide) for approximately 3–4 hours at 100 Volts. 0.5-
10 kb RNA ladder (Invitrogen) was used for size
comparison. The RNA was then capillary transferred over-
night onto Hybond-N+ nylon membrane (Invitrogen) and
UV cross-linked. Membranes were probed with a 539
bp cDNA probe designed to exons 24–27 of mouse LRRK2
(generated by PCR using primers forward 5’ATGCCAC
GTATCACCAAC’3, reverse 5’TCTAAGGTGCTGATC
TGATTC’3). Probes were labeled with [α-32P] dCTP
(3000 Ci/mmole) (Perkin Elmer) using Ready to Go label-
ing beads (Invitrogen). Cross-linked membranes were pre-
incubated at 42°C in hybridization buffer (1X Denhardt’s
solution, 4X SSC, 50 % (w/v) deionised formamide, 10 %
(w/v) dextran sulphate, 200 mg/μl herring sperm DNA) for
at least 30 minutes and then hybridized with labeled probe
overnight at 42°C. Membranes were washed with 1X SSC
for 20 minutes at room temperature to remove excess probe
and then 1–2 times in 1X SSC containing 0.1 % SDS at 55°C
for 15minutes. To visualize bands, membranes were exposed
to BioMax film (Kodak) at −80°C for 5–48 hours. A 214 bp
histone cDNA probe was used as loading control (generated
using primers forward 5’ GCGTGCTAGCT GGATGTCTT
‘3 and reverse 5’CCACTGAACTTCTGATTCGC ‘3).
Antibodies
Antibody 1182E, raised to amino acids 841–960 of
LRRK2 (1:200) was a gift from Dr. Benoit Giasson (Univ.
Pennsylvania) was used for immunoblotting. LRRK2
immunohistochemistry was performed with MJFF2 at
1:4000 (Epitomics, c41-2) raised to amino acids 970–
2527. Tyrosine hydroxylase (TH) (Affinity Bioreagents)
was used to visualize dopamine neurons by immunohis-
tochemistry (1:200) and on immunoblots (1:1000). Phos-
pho-TH (Ser40) antibody was used for immunoblotting
only (1:1000, Cell Signalling). Detection of α-synuclein
was with a mouse monoclonal to α-synuclein (clone 42,
1:3500 for immunohistochemistry and 1:500 for immu-
noblots) from BD Transduction Labs and the phospho-
Ser129 antibody (1:1000) was a gift from Dr. Takeshi
Iwatsubo, University of Tokyo. Activated microglia were
detected by Iba-1 (1:2000, Wako Chemicals). Tau anti-
bodies were CP-13 (1:1000 immunohistochemistry,
1:200 immunoblots), Tau-5 (1:500 immunoblots) and
PHF-1 (1:500 immunoblots) all gifts from Dr. Peter
Davies, Albert Einstein College of Medicine, 12E8
(1:10,000 immunohistochemistry) a gift from Dr. Peter
Seubert, Elan Pharmaceuticals and Tau-1 (1:500 immu-
noblots) from Millipore. For autophagy studies we used
LC3 (1:500 immunoblots) from Novus and p62 (1:500
for immunoblots and 1:2000 for immunohistochemistry)from Progen. Neurogenesis studies utilized rat α-5-
bromo-2-deoxyuridine (BrdU) 1:500 (Oxford Biotech-
nology) and goat α-doublecortin (DCX) 1:500, (Santa
Cruz Biotechnology).
Immunoblotting
Analysis of LRRK2 and tau protein was performed as
previously described [47]. TH and pTH immunoblotting
lysates were prepared in RIPA buffer with Triton X-100
containing protease inhibitors. 10 μg (for TH) or 50 μg
(pTH) of protein was loaded onto 4-12 % Bis-Tris gels
(Invitrogen). For autophagy studies samples were pre-
pared as previously described [34], 60 μg of protein was
loaded on 4-20 % Tris-glycine gels for LC3 and 10 %
Tris-glycine gels for p62. ImageJ 1.42q (National
Institutes of Health) was used to quantify blots.
Densitometric values were analyzed statistically by either
Student’s t-test or Mann Whitney non-parametric
comparisons.
Stereology
Brains from 18–20 month old KO (n = 4) and littermate
WT mice (n = 4) were post-fixed in 4 % paraformalde-
hyde (PFA) for 24 hours followed by 30 % sucrose cryo-
protection for 48 hours. Brains were sectioned
exhaustively at 50 μm thickness using a freezing sledge
microtome. For dopamine neuron and dendritic esti-
mates, after a random start, every third section was
stained free floating with TH antibody. Free floating
immunostaining was performed utilizing the VECTAS-
TAIN® ABC System (Vector laboratories). Sections were
mounted onto glass slides, allowed to dry overnight,
lightly counterstained with cresyl-violet and then dehy-
drated and cover slipped. Quantification was performed
at high magnification (400X) using the optical fractiona-
tor number and length probes in Stereo Investigator
software (MicroBrightField). Data was plotted as mean ±
SEM and statistically analyzed by Student’s t-test.
High performance liquid chromatography (HPLC)
HPLC with electrochemical detection was performed as
previously described [47] in striatal tissue punches from
frozen brains from mice aged 10 months KO (n = 14; 6
males, 8 females) and WT (n = 13; 7 males, 6 females)
and 16–18 months KO (n = 7; 4 males, 3 females) and
WT controls (n = 8; 4 males, 4 females). The amounts of
monoamines/metabolites in the tissue samples were
determined by comparing peak area values with those
obtained from external standards run on the same day.
Neurochemical concentrations were determined by nor-
malizing samples to protein concentrations obtained
from the pellets (BCA method). Data was plotted (mean
± SEM) and statistically analyzed using Mann Whitney
non-parametric comparisons.
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KO (n = 10 males), HET (n = 6 males) and WT litter-
mates (n = 13 males) aged 3–4 months were anesthetized
with 1-2 % isoflurane. Guide cannulae (CMA Microdia-
lysis) were surgically implanted into the striatum using a
standard stereotaxic frame (Kopf Instruments, Tujunga,
CA) utilizing coordinates (from Bregma anterior-poster-
ior +0.1 cm, lateral-medial +0.2 cm, dorso-ventral
−0.2 cm) according to the Mouse Brain Atlas [55]. Mice
were allowed to recover for at least 24 hours. Microdia-
lysis experiments were carried out on conscious, freely
moving mice with surgically implanted guide cannulae.
On the day of the experiment, the stylet in the guide
cannula was replaced with the microdialysis probe
(CMA/7 with 2 mm membrane, CMA Microdialysis).
The probe was perfused at 2 μl/min with artificial cere-
brospinal fluid (aCSF; 145 mM NaCl, 1.2 mM CaCl2,
3 mM KCl, 1.0 mM MgCl2) for a two hour equilibration
period before collection. Dialysate samples were auto-
matically collected every 15 minutes into vials contain-
ing 2 μl perchloric acid (0.1 %) to retard oxidation of
monoamines. Four baseline collections were taken at 15
minute intervals, and then the perfusate was switched to
high KCl aCSF (103 mM NaCl, 1.2 mM CaCl2, 45 mM
KCl, 1.0 mM MgCl2). After 30 minutes the perfusate
was switched back to the original aCSF and four subse-
quent samples were collected every 15 minutes. Samples
were analyzed by HPLC for dopamine content. Data was
plotted (mean ± SEM) and statistically analyzed using
Mann Whitney non-parametric comparisons.
Pathological analysis
At least six mice from each genotype (KO, HET, WT)
were analyzed per time point (3, 6, 12, 18 months). For-
malin fixed, paraffin embedded tissue sections were
dewaxed in xylene and rehydrated in descending alco-
hols and water. For antigen retrieval in paraffin sections,
tissue was pressure cooked (10 minutes) in distilled
water (all antibodies, except α-synuclein). Appropriate
disease/tissue positive controls were included for each
antibody (diffuse Lewy body disease for α-synuclein,
Alzheimer for tau antibodies, Alzheimer/vascular de-
mentia for Iba-1). Immunohistochemistry was performed
using the Dako Autostainer. Tissue was quenched for
endogenous peroxidases in 0.03 % H2O2 and blocked in
Dako All-purpose blocking solution for 30 minutes.
Primary antibody was incubated for 45 min at room
temperature. All secondary antibodies were from the
Envision+ System Labeled Polymer HRP (Dako), fol-
lowed with DAB substrate (Dako), with the exception of
p62 immunostaining which utilized an anti-guinea pig
secondary and DAB kit (both Vector Labs). Sections
were lightly counter stained in Gills 3 hematoxylin.
Standard histological staining was also used (haemotoxylinand eosin, Gomori's Prussian blue, Periodic acid-Schiff and
Masson Fontana).
Transmission electron microscopy
18 month old KO and WT mice, were perfused transcar-
dially with 2.5 % gutaraldehyde-2 % PFA in 0.1 M caco-
dylate buffer. Kidneys were removed, split in halves and
immersed in the same fixative for two hours at room
temperature. Small pieces of the cortex were further
fixed in aqueous 2 % OsO4 and 2 % uranyl acetate, dehy-
drated in ethanols and propylene oxide, infiltrated and
embedded in Epon 812 (Polysciences). Ultrathin sections
were stained with uranyl acetate and lead citrate, and
examined with a Philips 208 S electron microscope (FEI)
fitted with a Gatan 831 Orius CCD camera (Gatan).




Twenty eight littermate mice (N = 8 KO males KO; 8
KO females, and N = 6 WT males; 6 WT females)
were used for the evaluation of the exploratory activ-
ity in the open-field test. Open-field behavior of the
mice was evaluated in a longitudinal experiment, with
the first test applied at the age of 7 months and the
second at the age of 16 months. Mice were habitu-
ated to the behavioral room for one week before test-
ing. The OF apparatus consisted of a circular arena,
120 cm in diameter, surrounded by a 30 cm high
wall. The apparatus, build of white plastic, was ele-
vated 86 cm off the floor level. The arena was illumi-
nated by 4 sets of in ceiling fluorescent lights
available in a testing room and no additional illumin-
ation was used. An object (a plastic water bottle,
10 cm in diameter, 25 cm high) painted with black
and white horizontal stripes was placed in the centre
of the arena. All mice were individually exposed to
the arena in one 5-min session. At the onset of the
session, a mouse was placed near the wall of the
arena and its movement on the arena throughout the
duration of the session was recorded by a video
tracking system (HVS Image Advanced Tracker
VP200, HVS Image, Buckingham, UK). The data were
extracted off-line using a Wintrack program [56].
XIn our analysis we focused on measures of motor ac-
tivity in the arena and the exploration of a novel object.
The following behavioral categories were used to evalu-
ate the exploratory motor activity of mice in the open-
field: walking path length (m) – the distance a mouse
covered during the exploration of the arena, walking
speed (m/s) – averaged speed of active walking, exclud-
ing period of rests, latency to move – the onset (s) of ac-
tive locomotor exploration after placing a mouse in the
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of inactivity lasting between 1 and 5 s which was sepa-
rated by at least 1 s of locomotion, number of rests – a
rest was defined as a period of inactivity lasting longer
than 5 s which was separated by at least 1 s of locomo-
tion, time spent resting – total time (s) spent by mice on
resting, % time in the central zone – the percent of time
spend in the central zone of the arena (50 cm radius
from the centre), thigmotaxis – percent of time a mouse
continuously walked within the close vicinity (7.5 cm) of
the wall of the apparatus, path tortuosity (°/m) – the
measure was derived by dividing the path into straight
segments and curves with consistent change in direction.
Following, absolute changes in direction of all curves
were summed and divided by total path length. The
novel object exploration was evaluated by the latency (s) of
the first approach to the object, the total time of object ex-
ploration – a mouse was considered exploring an object if
its nose was within a direct contact or 1 cm from an ob-
ject and the body of a mouse was within a distance of
5 cm from the object perimeter, and by the number of
crosses of an object zone – a 5 cm virtual zone surrounding
an object.
A factorial model analysis of variance (ANOVA) with the
genotype as between subject, and age of testing (7 and
16 months) as within subject (repeated measure) factors
was used in the analysis of open-field data. While perform-
ing all repeated measures ANOVAs, departures from the
assumption of compound sphericity were evaluated by
Mauchly test [SPSS statistical package (SPSS Inc. Chicago)
v. 19 run on a Macintosh computer] with α level set to
0.05. In cases when sphericity was significantly violated,
degrees of freedom were adjusted by Greenhouse-Geisser
ε-correction. Due to considerable variability of the mea-
sures obtained in the open-field [45] and relatively small
sample size of mice, the interaction effect in our 2 × 2 fac-
torial design often did not reach significance at α = 0.05.
Consequently, we followed the overall ANOVAs by the a
priori identified analysis focused on genotype effect at each
testing age, utilizing Student’s t-tests for independent and
matched-pairs samples. Correlations between the variables
obtained in the open-field test were done using Pearson
product–moment correlation. The critical α level for all
analyses was set to 0.05. Due to space limitation, only sig-
nificant results pertaining to the hypotheses testing the ef-
fect of the genotype and age are reported.
Rotarod
Motor co-ordination was measured using an automated
rotarod system (Rotamex-5 Columbus instruments). Fol-
lowing a 3 day habituation period in the behavioral suite,
littermate mice (7 months KO n= 9; HET n = 8 and WT n
= 12) were trained for two days prior to testing. The spindle
dimensions were 3.0 cm x 9.5 cm and the speed of the rodwas set to 4-40 rpm acceleration, increasing 1 rpm every 5
seconds. The equipment was equipped with a sensor that
automatically stops the timer if the mice cling and roll
around on the rod. On the third day, mice were tested for 4
consecutive trials, allowing 10 minutes rest per trail. Data
from the testing day was plotted as mean trail time and
data was statistically analyzed using one way ANOVA fol-
lowed by Tukey’s multiple comparisons.
Gait dynamics
Mice (KO n = 8; HET n = 8 and WT n= 9) were selected
from the same group of animals described above for
rotarod testing. Mouse gait dynamics were obtained using a
motorized treadmill (with a transparent belt and digital
video camera mounted underneath) by ventral plane vide-
ography [57-59] and analyzed with DigiGait® Version 9 soft-
ware (Mouse Specifics, Inc). Each mouse was individually
placed in the treadmill compartment for a few seconds and
then the belt was turned on at a low speed (4 cm/sec) just
prior to testing [previous studies show that C57BL/6 J mice
do not require extended acclimatization to the treadmill
[57-59]]. The motor speed was then set to 14 cm/s and at
least 4 seconds of videography was collected for each
mouse to obtain at least 8 sequential step images. The
speed was then increased to 18 cm/s, and then 24 cm/sec,
collecting an average 4 seconds of videography to obtain at
least 12 or 15 sequential step images, respectively. Mice
that did not have stride regularity indices (alternate step
sequences) at 100 % [58,60] were still included in the study
to evaluate inter-limb coordination.
Each individual gait signal per limb consists of a stance
duration (time in contact with surface) and swing duration
(time not in contact with surface) which together are the
stride duration. Stride frequency is calculated by measuring
the number of strides over time. Stride length is calculated
by dividing the belt speed over the stride frequency. Paw
angles and step angles at full stance are determined by soft-
ware geometry calculations (fitting ellipses to the paws) of
ellipse centers, major axes and vertices. The left and right
gait measurements were combined for all forelimb and
hindlimb data analysis. Gait indices were plotted as mean ±
standard deviation and analyzed by one way ANOVA.
Supplemental methodology is also available in Additional
file 7.
Additional files
Additional file 1: Figure S1. No compensatory changes are observed in
the expression levels of murine LRRK1, SNCA (MAPT or PARKIN genes in
LRRK2 KO mice. Real-time PCR was performed with ABI TaqMan® probes
to murine (A) LRRK1 (Mm00713303_m1), (B) murine SNCA
(Mm00447333_m1), (C) MAPT (Mm00521988_m1) and (D) PARKIN
(Mm00450187_m1). Mouse GAPDH (Mm99999915_m1) as the
endogenous reference gene. Data plotted as mean ± SEM. In each
graph/region the first column is WT, second column HET and third
column is KO.
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function is normal in LRRK2 KO mice. (A) Dopamine uptake was
measured in freshly prepared synaptosomes using [2,5,6,7,8-3H]-DA. Each
experiment included N=3 mice per genotype (8 months of age) and
three independent experiments were performed. Specific DA uptake
values (pmol/mg/min) were averaged and expressed as % of WT control.
Data plotted as mean ± SEM. (B, C) To examine D2 autoreceptor
function, mice were treated with D2 receptor antagonist raclopride and
sacrificed 30 minutes later. Dopamine and dopamine metabolite levels
were measured by HPLC. Dopamine turnover, defined by the ratio of (B)
DOPAC/DA or (C) HVA/DA significantly increased, as expected, in all three
groups (p < 0.001 ANOVA for both ratios) however post-hoc
comparisons revealed the extent of this turnover increase did not differ
between WT, HET and KO groups. Data plotted as mean ± SEM.
Additional file 3: Figure 3. Post synaptic D1 and D2 receptor density is
comparable in LRRK2 KO and WT mice. Quantitative autoradiography was
performed with D1 receptor ligand [3H] SCH 23390 and D2 receptor
ligand [3H] methylspiperone in serial striatal sections in mice aged 10
months (A,B) and 18 month (C,D). D1 and D2 binding was equivalent in
KO and WT mice at both age points. Data plotted as mean ± SEM.
Additional file 4: Figure 4. Loss of LRRK2 does not impact on striatal
dendritic spine density. Dendritic spines were visualized in 18 month old
WT and KO mice by Golgi-Cox impregnantion and counted using
Metamorph software. (A) Representative lower magnification image of a
typical MSN selected for quantification - only dendrites clearly associated
with an MSN-like cell body were quantified (B) High magnification of a
dendrites captured by Z-stack shows that KO and WT spines appear to
be comparable (C) Quantification of spines, classified by morphological
type, revealed no difference between WT and KO dendrites. Data plotted
as mean ± SEM.
Additional file 5: Figure 5. Subgranular zone proliferation and
neurogenesis are unaffected in LRRK2 KO mice. (A) Proliferation was
measured by counting BrdU positive cells in sections prepared from mice
aged 4 months (N=4 per group) sacrificed 24 hours after IP BrdU
injection (100mg/kg) (B) Neurogenesis was quantified in the same
sections by counting doublecortin (DCX) positive neurons. Data plotted
as mean ± SEM.
Additional file 6: Figure 6. Tau regulation in LRRK2 KO mice does not
differ from WT. Cortical and hippocampal lysates were prepared from 18
month old WT and KO mice and immunoblots probed with tau
antibodies. Graph shows representative blots for Tau-5 tau, CP-13
(pSer202) and Tau-1 in alkaline phosphatase (dephosphorylated) treated
lysates. Densitometric quantification of N=6 mice per group (not shown)
did not reveal any significant differences in either region for KO versus
WT mice.
Additional file 7: Supplemental Methodology [26,47,61-63].
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